INTERACTIONS OF CANCER SUSCEPTIBILITY GENES AND ENVIRONMENTAL CARCINOGENS

Joint Meeting Organized by the American Association for Cancer Research (AACR) and the International Agency for Research on Cancer (IARC)

November 9-13, 1993
Lyon, France

CONFERENCE CHAIRPERSONS
Frederick P. Li / Boston, USA
Ruggero Montesano / Lyon, France

PROGRAM COMMITTEE
Kari K. Alitalo / Helsinki, Finland
J. Carl Barrett / Research Triangle Park, USA
Valerie Beral / Oxford, England
Dirk Bootsma / Rotterdam, The Netherlands
Curtis C. Harris / Bethesda, USA
Henry C. Piltot / Madison, USA
Bruce A. J. Ponder / Cambridge, England
Carmen Sapienza / La Jolla, USA
Takashi Sugimura / Tokyo, Japan
Lorenzo Tomatis / Lyon, France
Lee W. Wattenberg / Minneapolis, USA
I. Bernard Weinstein / New York, USA

SCIENTIFIC PROGRAM

Introductory Lectures
Curtis C. Harris / Bethesda, USA
Lorenzo Tomatis / Lyon, France
Lee W. Wattenberg / Minneapolis, USA
Manfred F. Rajewsky / Essen, Germany

Genetic Instability
Kari K. Alitalo / Helsinki, Finland
T. Heidmann / Paris, France
Thea D. Tisty / Chapel Hill, USA

Experimental Models of Genetic Susceptibility
J. Carl Barrett / Research Triangle Park, USA
Henry C. Piltot / Madison, USA
Bernard M. Mechler / Heidelberg, Germany

DNA Damage and Repair
Dirk Bootsma / Rotterdam, The Netherlands
John M. Essigmann / Cambridge, USA
Mutsuo Sekiguchi / Fukuoka, Japan

Mechanisms of Transgenerational Carcinogenesis
Carmen Sapienza / La Jolla, USA
Ulrike Wintersberger / Vienna, Austria
David Malkin / Toronto, Canada
Christopher J. Kemp / Glasgow, Scotland

Human Cancers
Frederick P. Li / Boston, USA
Valerie Beral / Oxford, England
Bruce A. J. Ponder / Cambridge, England
Neil E. Caporaso / Bethesda, USA
Gilbert M. Lenoir / Lyon, France

Markers of Individual Exposure
Ruggero Montesano / Lyon, France
Peter A. Cerutti / Epalinges, Switzerland

Opportunities for Prevention
I. Bernard Weinstein / New York, USA

Applicants are encouraged to submit abstracts for poster presentation.

Information and Application Forms
American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483
(215) 440-9300 (215) 440-9313 (FAX)
AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Cell Death in Cancer and Development

October 17-21, 1993
Chatham Bars Inn, Chatham (Cape Cod), Massachusetts

CONFERENCE CHAIRPERSON
Alan R. Eastman / Hanover, NH

PROGRAM COMMITTEE
Nathan A. Berger / Cleveland, OH
H. Robert Horvitz / Boston, MA
John T. Isaacs / Baltimore, MD
Stanley J. Korsmeyer / St. Louis, MO
Thomas R. Tritton / Burlington, VT
Andrew H. Wyllie / Edinburgh, Scotland

SCIENTIFIC PROGRAM

Keynote Address
Andrew H. Wyllie / Edinburgh, Scotland

Cell Death and Development
Martin C. Raff / London, England
H. Robert Horvitz / Boston, MA
Lawrence Schwartz / Amherst, MA
Hermann Steller / Cambridge, MA

Cell Death in the Pathogenesis of Cancer
John T. Isaacs / Baltimore, MD
Rolf Schulte-Hermann / Vienna, Austria
David P. Lane / Dundee, Scotland

Suppression of Cell Death
Stanley J. Korsmeyer / St. Louis, MO
Eileen White / Piscataway, NJ
William Sugden / Madison, WI
Ruth Craig / Hanover, NH

Enzymology of Cell Death
John A. Cidlowski / Chapel Hill, NC
Alan R. Eastman / Hanover, NH
Peter J.A. Devles / Houston, TX

Cell Death in the Immune System
Peter H. Krammer / Heidelberg, Germany
Douglas R. Green / La Jolla, CA
Jonathan D. Ashwell / Bethesda, MD
Arnold H. Greenberg / Winnipeg, Manitoba, Canada

Genetic Events Associated with Cell Death
J. John Cohen / Denver, CO
Barbara Osborne / Amherst, MA
Ralph E. Buttyan / New York, NY
Robert Schlegel / Boston, MA

Cell Death in Cancer Chemotherapy
Nathan A. Berger / Cleveland, OH
Yves G. Pommier / Bethesda, MD
Nancy L. Oleinick / Cleveland, OH
Carlos J. Carrera / San Diego, CA

Applicants are encouraged to submit abstracts for poster presentation.

Application Deadline: June 28, 1993

Information and Application Forms
American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Molecular Approaches to Cancer Immunotherapy

November 7-11, 1993
The Grove Park Inn, Asheville, North Carolina

CONFERENCE CHAIRPERSON

Ralph A. Reisfeld / La Jolla, CA

SCIENTIFIC PROGRAM

Keynote Address
Giorgio Trinchieri / Philadelphia, PA

Monoclonal Antibodies for Tumor Therapy
Alan N. Houghton / New York, NY
Albert F. LoBuglio / Birmingham, AL
Ira Pastan / Bethesda, MD
David A. Scheinberg / New York, NY

Genetically Engineered Antibodies
Stephen D. Gillies / Lexington, MA
Jeffrey Schlom / Bethesda, MD
Richard P. Junghans / Boston, MA
Sherie L. Morrison / Los Angeles, CA
Clive Woodhouse / Mountain View, CA

Gene Therapy of Cancer
James J. Mulé / Palo Alto, CA
Drew M. Pardoll / Baltimore, MD
David T. Currie / Chapel Hill, NC
Patrick Hwu / Bethesda, MD
Elizabeth Jaffe / Baltimore, MD

Cytokines in Tumor Therapy
Steven Gillis / Seattle, WA
Roland Mertelsmann / Freburg, Germany
Ronald Levy / Stanford, CA
Terry Strom / Boston, MA

Tumor Antigens Recognized by T-Cells
Olivera J. Finn / Pittsburgh, PA
Per A. Peterson / La Jolla, CA
Martin A. Cheever / Seattle, WA
Michael T. Lotze / Pittsburgh, PA

Antibodies as Immunogens
Soldano Ferrone / Valhalla, NY
Dorothée Herlyn / Philadelphia, PA
Kenneth Foon / Lexington, KY
Alan N. Houghton / New York, NY

Future of Cancer Immunotherapy
Isaiah J. Fidler / Houston, TX
Paul M. Sondel / Madison, WI
Irwin D. Bernstein / Seattle, WA
Eugenie S. Kleinerman / Houston, TX

Applicants are encouraged to submit abstracts for poster presentation.

Information and Application Forms

American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483

215-440-9300 215-440-9313 (FAX)
AMERICAN ASSOCIATION FOR CANCER RESEARCH
SCIENTIFIC CONFERENCES: 1993-1994

OCTOBER 17-21, 1993
Cell Death and Cancer
Chairperson: Alan R. Eastman, Hanover, NH
Chatham Bars Inn, Chatham (Cape Cod), MA

NOVEMBER 7-11, 1993
Molecular Approaches to Cancer Immunotherapy
Chairperson: Ralph A. Reisfeld, San Diego, CA
Grove Park Inn, Asheville, NC

NOVEMBER 9-13, 1993
Interactions of Cancer Susceptibility Genes and Environmental Carcinogens
Joint Meeting with International Agency for Research on Cancer (IARC)
Chairpersons: Frederick P. Li, Boston, MA, and Ruggero Montesano, Lyon, France
IARC, Lyon, France

DECEMBER 5-9, 1993
Cell Signalling and Cancer Treatment
Joint Meeting with British Association for Cancer Research and European Organisation for Research and Treatment of Cancer (PAM Group)
Chairpersons: Garth Powis, Tucson, AZ; Paul Workman, Glasgow, Scotland
El San Juan Hotel, San Juan, PR

JANUARY 17-22, 1994
Risk Assessment in Environmental Carcinogenesis
Co-Sponsored by the Environmental Mutagen Society
Chairpersons: Philip C. Hanawalt, Stanford, CA; James A. Swenberg, Chapel Hill, NC
Whistler Resort and Conference Center, Whistler, B.C., Canada

JANUARY 31-FEBRUARY 5, 1994
Molecular Genetics of Progression and Metastasis
Chairperson: Lance A. Liotta, Bethesda, MD
Big Sky Resort, Big Sky, MT

FEBRUARY 19-24, 1994
Cancer: Perturbation in Cell Cycle Control and Genomic Integrity
Chairpersons: Thea D. Tlsty, Chapel Hill, NC; Lawrence A. Loeb, Seattle, WA
Banff Springs Hotel, Banff, Alberta, Canada

MARCH 5-11, 1994
Growth Factors, Development, and Cancer
Joint Meeting with Friedrich-Miescher Institut
Chairpersons: Harold L. Moses, Nashville, TN; Bernd Groner, Basel, Switzerland
Congress Center, Interlaken, Switzerland

APRIL 10-13, 1994
85th Annual Meeting
Chairperson: Karen S. H. Antman, Boston, MA
Moscone Convention Center, San Francisco, CA

OCTOBER 16-20, 1994
Transcriptional Regulation in Differentiation (Tentative Title)
Chairpersons: Eric N. Olson, Houston, TX; Bruce M. Spiegelman, Boston, MA
Chatham Bars Inn, Chatham (Cape Cod), MA

AACR members will receive brochures on the above special conferences as soon as they are available. Nonmembers should call or write:
American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483
215-440-9300 • 215-440-9313 (FAX)
AMERICAN CANCER SOCIETY CLINICAL AWARDS

The American Cancer Society is proud to announce its Clinical Awards for 1994. Funding the Clinical Oncology Fellowship (COF), the Clinical Oncology Career Development Award (CDA), and the Cancer Control Career Development Award for Primary Care Physicians (CCDDA).

The COF is a one-year institutional award intended to support a multidisciplinary training experience for physicians and dentists preparing for a leadership career in academic oncology. The Fellowship is expected to provide unique training in addition to that which is normally provided in postgraduate training programs designed to fulfill requirements of specialty boards. The COF stipend is $10,000 per year.

The CDA is a three-year award given to promising junior faculty who will pursue academic careers in clinical oncology. A successful application must describe in detail a supervised program that will develop the candidate's clinical expertise and his/her capacity to perform independent clinical/laboratory research. The annual stipend for the CDA is $25,000 for the first year, and $30,000 and $35,000 for the second and third years, respectively.

In order to encourage and support activities in cancer control, the Society offers a limited number of CCCDA's to physicians specializing in primary care. It is anticipated that physicians trained under these two-year grants will improve cancer control through involvement in primary care practice, education, and research activities related to cancer control. These awards are intended to develop academic leaders in primary care specialties emphasizing cancer control.

Please note that candidates for these awards must be citizens or permanent residents of the United States. The application deadlines for each of these awards are as follows:

- Clinical Oncology Fellowship: July 1, 1993
- Clinical Oncology Career Development Award: August 1, 1993
- Cancer Control Career Development Award: August 15, 1993

To request additional information or application materials for these programs, contact the office of:

Virginia Krawiec, M.P.A.
Professional Education Department
American Cancer Society, Inc.
1599 Clifton Road, N.E.
Atlanta, GA 30329-4251
404-329-5734

AMERICAN CANCER SOCIETY

CLINICAL ONCOLOGY FELLOWSHIPS

The American Cancer Society is pleased to announce the 1994 Clinical Oncology Fellowships (COF). The COF is intended to support a multidisciplinary training experience for physicians and dentists preparing for a leadership career in academic oncology. The program may include training in cancer control, prevention, detection, diagnosis, therapy, rehabilitation, and research. The Fellowship is expected to provide unique training in addition to that which is normally provided in postgraduate training programs designed to fulfill requirements of specialty boards, and it is available to citizens or permanent residents of the United States only.

Applications are to be submitted by institutions (not prospective fellows) by July 1, 1993 for fellowships to begin July 1, 1994. The stipend for this one-year award is $10,000.

To request further information or application materials, please contact the office of:

Virginia Krawiec, M.P.A.
Professional Education Department
American Cancer Society, Inc.
1599 Clifton Road, N.E.
Atlanta, GA 30329-4251
404-329-5734

AMERICAN CANCER SOCIETY

CANCER CONTROL CAREER DEVELOPMENT AWARD FOR PRIMARY CARE PHYSICIANS

The American Cancer Society is pleased to announce the 1994 Cancer Control Career Development Award for Primary Care Physicians (CCDDA). This award is intended to develop academic leaders in primary care specialties emphasizing cancer control: family practice, general internal medicine, obstetrics and gynecology, and pediatrics. Through the CCDDA, the Society seeks to support individuals in supervised programs that will develop the candidate's clinical and teaching expertise and his/her capacity to perform independent clinical research in cancer control. It is anticipated that physicians trained under these awards will improve cancer control through involvement in primary care practice, education, and research activities related to cancer control.

Candidates for first year Cancer Control Career Development Awards for Primary Care Physicians may not have an academic rank above that of Assistant Professor and must not be tenured or be the section head (or equivalent) of his/her discipline. These awards are intended to support the early development of academic careers which place emphasis on cancer control; physicians with well established careers and substantial research funding should not apply. In addition, candidates for these awards must be citizens or permanent residents of the United States.

This is a two-year award. The stipend for the award is $25,000 for the first year, and $30,000 for the second, and $35,000 for the third. The application deadline is August 1, 1993 for awards to begin July 1, 1994.

To request further information or application materials, please contact the office of:

Virginia Krawiec, M.P.A.
Professional Education Department
American Cancer Society, Inc.
1599 Clifton Road, N.E.
Atlanta, GA 30329-4251
404-329-5734
Henry Mihich, M.D., in a 30-year career, has achieved distinction primarily from his studies on the interaction of drugs with the immune system as they affect cancer cell growth. As a part of these investigations, he demonstrated: that host immune defense is indispensable to the antitumor effects of diverse chemotherapeutic agents against transplantable mouse tumors; that mouse leukemic sublines resistant to certain antitumor agents are more immunogenic and antigenic than the parent cell lines; that certain anticancer agents selectively inhibit preformed immune effector functions; that Adriamycin selectively augments macrophage differentiation, increasing cytotoxic T-lymphocyte responses and inhibiting interleukin 1 production; and that the cyclophosphamide metabolite 4-hydroxyperoxycyclophosphamide inhibits selectively precursors of T-suppressor cells.

In addition to these fundamental studies, he has brought various drugs to clinical trial, including methylglyoxal bis (guanylhydrazone). His work has been published in 107 papers and reviewed in 23 book chapters and 14 symposium lectures.

As Director of the Grace Cancer Drug Center at Roswell Park Cancer Institute, Buffalo, NY, he has built a strong department focused on medicinal chemistry, preclinical biochemical pharmacology, and experimental therapeutics. He has been cognizant of the need to develop a strong basic background on the fundamental nature of cancer to improve drug treatment and has strengthened collaboration of basic with clinical departments. As Chairman of the Pharmacology Department within the Roswell Park Division of the Graduate School of the State University of Buffalo, he heads a department that currently has 17 predoctoral students and 23 postdoctoral fellows.

He has contributed significantly to the advancement of cancer research and treatment through his membership on policy-making bodies such as the Board of Scientific Counselors of the National Cancer Institute's Division of Cancer Treatment and the National Cancer Advisory Board, and as President of the American Association for Cancer Research (1987–1988). He has also participated in numerous cooperative working groups between the United States and France, Italy, and Japan, and has served on nine study sections and on the editorial boards of 12 peer-reviewed journals.

Edwin A. Mirand